Lin Chen

机构：Nanchang University, People 's Hospital of Jilin Province, Second Affiliated Hospital of Nanchang University · ORCID：0000-0001-7905-2505

发表论文 131 篇 · 总被引 2270 次 · h-index 24

代表论文

• Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 56)
• Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial (2024 · Journal of Hematology & Oncology · 被引 36)
• Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial (2025 · Annals of the Rheumatic Diseases · 被引 22)
• Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications (2024 · Biomarker Research · 被引 22)
• Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer (2024 · Journal of Ethnopharmacology · 被引 16)
• Gastrointestinal traits, common inflammatory disorders, gallstones, and biliary tract cancer: A network Mendelian randomization study (2025 · Journal of Advanced Research · 被引 7)